Evidence map›Paper›PMID 40163686›Full record

ArticleThe oncologist2025

Clinical outcomes of recurrent or metastatic head and neck cancer after failure of platinum and nivolumab: a multicenter retrospective study.

Takane Watanabe, Hiroki Oka, Kengo Nagashima, Hideaki Nishi, Yoshihiko Kumai, Hiroaki Iijima, Kenji Okami, Yasushi Shimizu, Satoshi Kano, Kazue Ito and 11 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Takane WatanabeDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 104-0045, 5-1-1, Tsukiji, Chuo-ku, Tokyo, Japan.ORCID 0009-0008-3817-9874
Hiroki OkaDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 104-0045, 5-1-1, Tsukiji, Chuo-ku, Tokyo, Japan.
Kengo NagashimaBiostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo 160-0016, Japan.ORCID 0000-0003-4529-9045
Hideaki NishiOtorhinolaryngology/Head and Neck Surgery, Nagasaki University Hospital, Nagasaki 852-8501, Japan.
Yoshihiko KumaiOtorhinolaryngology/Head and Neck Surgery, Nagasaki University Hospital, Nagasaki 852-8501, Japan.
Hiroaki IijimaOtorhinolaryngology/Head and Neck Surgery, Tokai University Hospital, Isehara 259-1193, Japan.
Kenji OkamiOtorhinolaryngology/Head and Neck Surgery, Tokai University Hospital, Isehara 259-1193, Japan.
Yasushi ShimizuDepartment of Medical Oncology, Hokkaido University Hospital, Sapporo 060-8648, Japan.
Satoshi KanoOtorhinolaryngology, Head and Neck Surgery, Hokkaido University Hospital, Sapporo 060-8648, Japan.
Kazue ItoHead and Neck Oncology, Miyagi Cancer Center, Natori 981-1239, Japan.
Tomoko YamazakiHead and Neck Oncology, Miyagi Cancer Center, Natori 981-1239, Japan.
Hideaki TakahashiOtorhinolaryngology, Yokohama City University Hospital, Yokohama 236-0004, Japan.
Nobuhiko OridateOtorhinolaryngology, Yokohama City University Hospital, Yokohama 236-0004, Japan.
Tomoya YokotaGastrointestinal Oncology Department, Shizuoka Cancer Center, Shizuoka 411-8777, Japan.ORCID 0000-0001-7327-7949
Taiji KoyamaDepartment of Medical Oncology and Hematology, Kobe University Hospital, Kobe 650-0017, Japan.
Naomi KiyotaDepartment of Medical Oncology and Hematology, Kobe University Hospital, Kobe 650-0017, Japan.ORCID 0000-0001-8021-6116
Yasuyoshi SatoDepartment of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.ORCID 0000-0003-4145-8694
Shunji TakahashiDepartment of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.ORCID 0000-0002-5031-1953
Kyoko KatoDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan.
Shigenori KadowakiDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan.ORCID 0000-0001-9923-5309
Yoshitaka HonmaDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 104-0045, 5-1-1, Tsukiji, Chuo-ku, Tokyo, Japan.ORCID 0000-0002-4209-4493

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPlatinum and anti-PD-1 antibodies are the front-line systemic therapy for recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC). However, limited data are available on clinical outcomes and appropriate regimens for patients with RM-HNSCC following treatment failure with these agents. PATIENTS AND

methodsWe retrospectively analyzed the clinical data of patients with RM-HNSCC from 10 Japanese institutions in whom platinum and nivolumab treatment failed.

resultsOf the 480 patients included in the study, 236 were treated with the best supportive care and had a median overall survival of 3.1 months. The remaining 244 patients received salvage-line chemotherapy, which was paclitaxel + cetuximab in 72 (30%), paclitaxel or docetaxel in 89 (36%), and tegafur/gimeracil/oteracil in 48 (20%); the respective objective response rates were 54.9%, 27.9%, and 25.5%, with median progression-free survival of 5.4 months and median overall survival of 13.0 months. Multivariable analysis identified disease stabilization or response on prior nivolumab and paclitaxel + cetuximab as salvage-line chemotherapy to be associated with encouraging progression-free and overall survival.

conclusionThis study sheds light on clinical outcomes and prognostic factors in patients with RM-HNSCC after failure of platinum and anti-PD-1 antibody therapy. The findings provide essential baseline data for future therapeutic development in salvage-line settings.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsHead and Neck NeoplasmsNeoplasm Recurrence, LocalNivolumabPlatinum CompoundsSquamous Cell Carcinoma of Head and NeckAdultAgedAged, 80 and overDocetaxelFemaleHumansMaleMiddle AgedNeoplasm MetastasisPaclitaxelDocetaxelNivolumabPaclitaxelPlatinum Compoundsbest supportive careimmune checkpoint inhibitorlong-term survivalnivolumabrecurrent or metastatic head and neck cancersalvage-line chemotherapy

Identifiers

PMID40163686
PMCPMC11957247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.